VF
QNCX icon

Virtu Financial’s Quince Therapeutics QNCX Stock Holding History

Virtu Financial’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79
Closed -$53K – 2174
2025
Q4 		$53K Buy
+79
New +$39.8K ﹤0.01% 1296
2025
Q2 		– Sell
-217
Closed -$58K – 1941
2025
Q1 		$58K Buy
217
+71
+49% +$21.7K ﹤0.01% 994
2024
Q4 		$55K Buy
+146
New +$43.9K ﹤0.01% 1145
2021
Q3 		– Sell
-27
Closed -$286K – 1874
2021
Q2 		$286K Buy
+27
New +$226K 0.03% 751
2020
Q3 		– Sell
-36
Closed -$336K – 1422
2020
Q2 		$336K Buy
+36
New +$330K 0.04% 509

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial's QNCX Position: Q1 2026 in Review

Virtu Financial sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 79 shares — an estimated $53K sold.

Virtu Financial first reported a position in QNCX in Q2 2020 and held it in 5 quarters. The position peaked at $336K in Q2 2020. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Virtu Financial reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 79 Quince Therapeutics shares in Q1 2026, an estimated $53K.
  • Virtu Financial first reported a position in Quince Therapeutics in Q2 2020 and held it in 5 quarters.
  • Virtu Financial's Quince Therapeutics position peaked at $336K in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.